Hepatitis E News and Research

RSS

Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).

Stressgen granted new U.S. patent for treatment of Hepatitis B

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins, and methods of treating an HBV infection using these fusion proteins.

7 Sep 2005

My body, my drugs, my world awarded for outstanding science

Melbourne researchers have been recognised for their major study of injecting drug use and hepatitis C risk in rural Australia.

6 Sep 2005

Shot in the arm for vaccines

A Flinders University research program to develop new forms of vaccine against infectious diseases has received over $3 million in funding from the United States Government's National Institutes of Health.

6 Sep 2005

Study suggests cirrhosis and liver disease nearly inevitable for people with hep C

Nearly 80 percent of chronic hepatitis C sufferers who have the disease for several decades will develop cirrhosis or end-stage liver disease later in life, according to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology.

1 Sep 2005

Designer molecules that combine metals such as copper with natural organic materials could treat diseases in the body

That's the finding of chemists at Ohio State University, who have successfully tested such molecules against portions of HIV and Hepatitis C virus RNA in the laboratory. They've also created molecules that act like ACE, or angiotensin-converting enzyme, inhibitors - drugs that are used to lower blood pressure.

30 Aug 2005

Emergent Biosolutions' typhoid vaccine achieves positive results in Phase II clinical study

Emergent BioSolutions today announced positive results from a Phase II clinical study evaluating a new simplified dosing regimen for the company's next generation single dose oral typhoid vaccine. The results of the study were published in the August edition of the Journal of Infectious Diseases.

30 Aug 2005

Discovery may significantly advance the treatment of cancers and infectious diseases

Current treatments frequently achieve only limited results with these types of diseases, which affect hundreds of thousands of Canadians.

29 Aug 2005

Immunity - another important function of the mitochondria

Researchers have discovered a surprise lurking inside mitochondria, the power plants that are present in every cell. It turns out that these powerhouses also contain a protein that triggers the immune system to attack viral invaders.

28 Aug 2005

Susceptibility to Hepatitis A in patients with chronic liver disease due to Hepatitis C virus infection: missed opportunities for vaccination

A new study examining whether patients with chronic Hepatitis C virus (HCV) were routinely vaccinated against Hepatitis A virus (HAV) found that vaccination rates were low, even though HAV vaccination is recommended for patients with chronic liver disease.

23 Aug 2005

Study examines the incidence and risk factors associated with Hepatitis C infection in rural Egypt

The prevalence of antibodies to Hepatitis C Virus (HCV) in Egypt is among the highest in the world. From the 1950s until 1982 hundreds of thousands were infected during mass campaigns to control schistosomiasis (a parasitic disease) using mass therapy with intravenous antimony compounds, but little is known about current risk factors and rates of transmission.

23 Aug 2005

C. elegans has similar virus-fighting mechanism as humans and can be used in research

Researchers at the University of California, Riverside have discovered that a simple worm, called C. elegans, makes an excellent experimental host for studying some of the most virulent viruses that infect humans.

17 Aug 2005

Interferon selectively kills colon cancer cells when combined with irinotecan chemotherapy agent

Johns Hopkins Kimmel Cancer Center scientists have found that interferon, used for 30 years to treat blood cancers, multiple sclerosis and hepatitis, selectively kills colon cancer cells when combined with another standard chemotherapy agent.

16 Aug 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

Natural killer cells help understand responses to bone marrow transplants

Scientists have discovered that a group of important immune system cells has a surprising resemblance to cinematic British superspy James Bond: the cells receive a "license" that allows them to unleash their most potent attacks on enemies.

4 Aug 2005

Infectious diseases pose a serious threat to the nation's public health

Infectious diseases pose a serious threat to the nation's public health. Today, experts addressed key developments to the current and future outlook of infectious diseases, highlighting adolescent immunizations, outbreaks and epidemics of infectious diseases, antimicrobial resistance and new developments in HIV medicine, at a press conference sponsored by the National Foundation for Infectious Diseases (NFID).

27 Jul 2005

Steady upward climb in child vaccinations

According to U.S. health officials, a record high rate of 81 percent of toddlers 19 months to 3 years old are now getting vaccinated with the full recommended series.

27 Jul 2005

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Researchers at The University of Texas M. D. Anderson Cancer Center have uncovered a crucial molecular link between a viral infection and development of a common and fatal form of liver cancer. In the process, they have identified a possible way to treat this disease as well as a number of other cancers.

26 Jul 2005

Acetaminophen, when taken as directed, is safe for patients with liver disease

Contrary to common perception, clinical data demonstrate that acetaminophen is an appropriate pain relief choice for patients with chronic liver disease. According to a systematic literature review of the data, which is published in the current issue of the American Journal of Therapeutics, there is no evidence that acetaminophen at therapeutic doses aggravates liver disease.